Vera Therapeutics (VERA) Competitors

Roivant Sciences (NASDAQ:ROIV) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.

Do analysts rate ROIV or VERA?

Roivant Sciences presently has a consensus target price of $17.93, indicating a potential upside of 58.03%. Vera Therapeutics has a consensus target price of $67.50, indicating a potential upside of 79.76%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Vera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.11

Does the media refer more to ROIV or VERA?

In the previous week, Vera Therapeutics had 8 more articles in the media than Roivant Sciences. MarketBeat recorded 13 mentions for Vera Therapeutics and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.91 beat Vera Therapeutics' score of 0.79 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings & valuation, ROIV or VERA?

Roivant Sciences has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$124.79M	66.18	$4.35B	$5.65	2.01
Vera Therapeutics	N/A	N/A	-$95.99M	-$2.61	-14.39

Is ROIV or VERA more profitable?

Roivant Sciences has a net margin of 3,827.42% compared to Vera Therapeutics' net margin of 0.00%. Roivant Sciences' return on equity of -14.65% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	3,827.42%	-14.65%	-13.19%
Vera Therapeutics	N/A	-50.13%	-39.50%

Which has more risk & volatility, ROIV or VERA?

Roivant Sciences has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Do institutionals and insiders believe in ROIV or VERA?

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Comparatively, 21.7% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor ROIV or VERA?

Roivant Sciences received 14 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 77.27% of users gave Roivant Sciences an outperform vote while only 63.79% of users gave Vera Therapeutics an outperform vote.

Company	Underperform	Outperform
Roivant Sciences	Outperform Votes 51 77.27%	Underperform Votes 15 22.73%
Vera Therapeutics	Outperform Votes 37 63.79%	Underperform Votes 21 36.21%

Summary

Roivant Sciences beats Vera Therapeutics on 12 of the 18 factors compared between the two stocks.